Chugai Pharmaceutical Co., Ltd. (CHGCY)
21.54
+0.34
(+1.60%)
USD |
OTCM |
Oct 23, 16:00
Chugai Pharmaceutical Enterprise Value : 65.07B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 65.07B |
| October 22, 2026 | 63.95B |
| October 21, 2026 | 61.71B |
| October 20, 2026 | 61.58B |
| October 19, 2026 | 59.47B |
| October 16, 2026 | 59.87B |
| October 15, 2026 | 59.90B |
| October 14, 2026 | 57.50B |
| October 13, 2026 | 57.43B |
| October 12, 2026 | 57.10B |
| October 09, 2026 | 57.23B |
| October 08, 2026 | 57.37B |
| October 07, 2026 | 57.73B |
| October 06, 2026 | 57.63B |
| October 05, 2026 | 57.73B |
| October 02, 2026 | 56.97B |
| October 01, 2026 | 57.79B |
| September 30, 2026 | 58.58B |
| September 29, 2026 | 57.60B |
| September 28, 2026 | 60.26B |
| September 25, 2026 | 63.45B |
| September 24, 2026 | 63.29B |
| September 23, 2026 | 64.84B |
| September 22, 2026 | 65.46B |
| September 21, 2026 | 65.16B |
| Date | Value |
|---|---|
| September 18, 2026 | 64.93B |
| September 17, 2026 | 64.61B |
| September 16, 2026 | 61.78B |
| September 15, 2026 | 62.57B |
| September 14, 2026 | 62.47B |
| September 11, 2026 | 62.47B |
| September 10, 2026 | 61.68B |
| September 09, 2026 | 62.99B |
| September 08, 2026 | 63.45B |
| September 04, 2026 | 65.23B |
| September 03, 2026 | 66.55B |
| September 02, 2026 | 65.16B |
| September 01, 2026 | 64.87B |
| August 31, 2026 | 65.10B |
| August 28, 2026 | 65.99B |
| August 27, 2026 | 65.46B |
| August 26, 2026 | 66.15B |
| August 25, 2026 | 66.09B |
| August 24, 2026 | 65.99B |
| August 21, 2026 | 67.20B |
| August 20, 2026 | 66.88B |
| August 19, 2026 | 66.91B |
| August 18, 2026 | 64.84B |
| August 17, 2026 | 64.77B |
| August 14, 2026 | 65.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 91.54B |
| Daiichi Sankyo Co., Ltd. | 31.63B |
| Eisai Co., Ltd. | 9.101B |
| Santen Pharmaceutical Co., Ltd. | 3.297B |
| Ono Pharmaceutical Co., Ltd. | 6.824B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 730.02M |
| Revenue (Quarterly) | 2.144B |
| Total Expenses (Quarterly) | 1.414B |
| EPS Diluted (Quarterly) | 0.2218 |
| Gross Profit Margin (Quarterly) | 69.49% |
| Profit Margin (Quarterly) | 34.06% |
| Earnings Yield | 4.31% |
| Operating Earnings Yield | 6.19% |
| Normalized Earnings Yield | 4.511 |